Comparison of remifentanil with dexmedetomidine for monitored anaesthesia care in elderly patients during vertebroplasty and kyphoplasty

Abstract

Objectives This clinical trial is registered at ClinicalTrials.gov. (NCT02476981) This randomized, prospective double-blind study compared remifentanil with dexmedetomidine for monitored anaesthesia care during minimally invasive corrections of vertebral compression fractures (vertebroplasty or kyphoplasty). Methods Patients > 65 years of age with American Society of Anesthesiologists (ASA) classification I–III, scheduled for vertebroplasty or kyphoplasty under monitored anaesthesia care, received remifentanil (i.v. infusion 1–5 µg/kg/h) or dexmedetomidine (loading dose 0.3–0.4 µg/kg followed by i.v. infusion 0.2–1 µg/kg/h) to maintain observer's assessment of alertness/sedation (OAA/S) scale <4 during the procedure. Results There were no statistically significant differences in demographic data between the remifentanil ( n = 37) and dexmedetomidine groups ( n = 38). Patients on dexmedetomidine experienced lower mean arterial pressure (MAP) and heart rate (HR), and higher SpO2 values, than patients on remifentanil. Compared with dexmedetomidine, remifentanil produced more respiratory depression, oxygen desaturation, and reduced the need for additional intraoperative opioids. There were no significant between-group differences in terms of recovery time, investigators’ satisfaction scores, or patients’ overall pain experiences. Conclusions During monitored anaesthesia care, dexmedetomidine provides less respiratory depression, lower MAP and HR, but also less analgesic effect than remifentanil in elderly patients undergoing vertebroplasty or kyphoplasty.